Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits

Blood

Volumn 123, Issue 13, 2014, Pages 2102-2107

  Yau, Jonathan W ^a,b   Liao, Peng ^a,b   Fredenburgh, James C ^a,b   Stafford, Alan R ^a,b   Revenko, Alexey S ^c   Monia, Brett P ^c   Weitz, Jeffrey I ^a,b,d  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ISIS PHARMACEUTICALS   (United States)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12;

ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; BLOOD CLOTTING; CATHETER OCCLUSION; CATHETER THROMBOSIS; CONTROLLED STUDY; DRUG EFFICACY; INTRAVENOUS CATHETER; JUGULAR VEIN; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; RABBIT;

ANIMALS; CATHETER OBSTRUCTION; CATHETERS; DISEASE MODELS, ANIMAL; FACTOR XI; FACTOR XII; GENE EXPRESSION REGULATION; GENETIC THERAPY; MALE; OLIGONUCLEOTIDES, ANTISENSE; RABBITS; RNA INTERFERENCE; SUBSTRATE SPECIFICITY; THROMBOSIS;

EID: 84897552463     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-12-540872     Document Type: Article

References (42)

1. Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood. 2013;122(14):2310-2317.
2. Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost. 2013;11(2):223-233.
3. Tagalakis V, Wharin C, Kahn SR. Comprehensive update on the prevention and treatment of venous thromboembolism in cancer patients. Semin Thromb Hemost. 2013;39(2):127-140.
4. Lee AY, Kamphuisen PW. Epidemiology and prevention of catheter-related thrombosis in patients with cancer. J Thromb Haemost. 2012;10(8):1491-1499.
5. Schiffer CA, Mangu PB, Wade JC, et al. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(10):1357-1370.
6. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(8):1687-1693. (Pubitemid 47207163)
7. Gailani D, Renné T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(12):2507-2513. (Pubitemid 350158899)
8. Vogler EA, Siedlecki CA. Contact activation of blood-plasma coagulation. Biomaterials. 2009;30(10):1857-1869.
9. Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA. 2007;104(15):6388-6393. (Pubitemid 47186104)
10. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A. 2006;103(4):903-908. (Pubitemid 43212194)
11. Yau JW, Stafford AR, Liao P, Fredenburgh JC, Roberts R, Weitz JI. Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Blood. 2011;118(25):6667-6674.
12. Yau JW, Stafford AR, Liao P, et al. Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. Acta Biomater. 2012;8(11):4092-4100.
13. Tang Y, Ho G, Li Y, et al. Beneficial metabolic effects of CB1R anti-sense oligonucleotide treatment in diet-induced obese AKR/J mice. PLoS ONE. 2012;7(8):e42134.
14. Hashimoto JG, Beadles-Bohling AS, Wiren KM. Comparison of RiboGreen and 18S rRNA quantitation for normalizing real-time RT-PCR expression analysis. Biotechniques. 2004;36(1):54-56, 58-60.
15. Wiebe EM, Stafford AR, Fredenburgh JC, Weitz JI. Mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide. J Biol Chem. 2003;278(37):35767-35774. (Pubitemid 37102353)
16. Klement P, Du YJ, Berry LR, Tressel P, Chan AK. Chronic performance of polyurethane catheters covalently coated with ATH complex: a rabbit jugular vein model. Biomaterials. 2006;27(29):5107-5117. (Pubitemid 43928119)
17. Saber W, Moua T, Williams EC, et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost. 2011;9(2):312-319.
18. Zhang H, Löwenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood. 2010;116(22):4684- 4692.
19. Revenko AS, Gao D, Crosby JR, et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood. 2011;118(19):5302-5311.
20. Younis HS, Crosby J, Huh JI, et al. Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood. 2012;119(10):2401-2408.
21. Crosby JR, Marzec U, Revenko AS, et al. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol. 2013;33(7):1670-1678.
22. Munakata M, Teraoka A, Komiyama Y, Masuda M, Murakami T, Murata K. Determination of the minimal concentrations of contact activation factors in deficient substrate plasmas required to assess accurately factor XII, factor XI, factor IX, and high molecular weight kininogen. Thromb Res. 1990;57(2):197-203. (Pubitemid 20071069)
23. Griffin JH, Cochrane CG. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci U S A. 1976;73(8):2554-2558.
24. Geng Y, Verhamme IM, Smith SB, et al. The dimeric structure of factor XI and zymogen activation. Blood. 2013;121(19):3962-3969.
25. Tans G, Griffin JH. Properties of sulfatides in factor-XII-dependent contact activation. Blood. 1982;59(1):69-75. (Pubitemid 12162347)
26. Tankersley DL, Alving BM, Finlayson JS. Activation of factor XII by dextran sulfate: the basis for an assay of factor XII. Blood. 1983;62(2):448-456. (Pubitemid 13036098)
27. van der Kamp KW, Hauch KD, Feijen J, Horbett TA. Contact activation during incubation of five different polyurethanes or glass in plasma. J Biomed Mater Res. 1995;29(10):1303-1306.
28. Zhuo R, Siedlecki CA, Vogler EA. Autoactivation of blood factor XII at hydrophilic and hydrophobic surfaces. Biomaterials. 2006;27(24):4325-4332. (Pubitemid 43674176)
29. Zhuo R, Siedlecki CA, Vogler EA. Competitive-protein adsorption in contact activation of blood factor XII. Biomaterials. 2007;28(30):4355-4369. (Pubitemid 47212410)
30. Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials. 2004;25(26):5681-5703. (Pubitemid 38624449)
31. Chan MY, Weitz JI, Merhi Y, Harrington RA, Becker RC. Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. J Thromb Thrombolysis. 2009;28(3):366-380.
32. Giugliano RP, Wiviott SD, Stone PH, et al; ANTHEM-TIMI-32 Investigators. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J Am Coll Cardiol. 2007;49(25):2398-2407. (Pubitemid 46962263)
33. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med. 2006;203(3):513-518.
34. Renné T, Pozgajová M, Grüner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202(2):271-281. (Pubitemid 41043823)
35. Tucker EI, Marzec UM, White TC, et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood. 2009;113(4): 936-944.
36. Matafonov A, Leung PY, Gailani AE, et al. Factor XII inhibition reduces thrombus formation in a primate thrombosis model [published online ahead of print January 9, 2014]. Blood.
37. Lin J, Deng H, Jin L, et al. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants. J Med Chem. 2006;49(26):7781-7791. (Pubitemid 46039665)
38. de Maat S, van Dooremalen S, de Groot PG, Maas C. A nanobody-based method for tracking factor XII activation in plasma. Thromb Haemost. 2013;110(3):458-468.
39. Woodruff RS, Xu Y, Layzer J, Wu W, Ogletree ML, Sullenger BA. Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. J Thromb Haemost. 2013;11(7):1364-1373.
40. Alibeik S, Zhu S, Yau JW, Weitz JI, Brash JL. Surface modification with polyethylene glycol-corn trypsin inhibitor conjugate to inhibit the contact factor pathway on blood-contacting surfaces. Acta Biomater. 2011;7(12):4177- 4186.
41. Alibeik S, Zhu S, Yau JW, Weitz JI, Brash JL. Dual surface modification with PEG and corn trypsin inhibitor: effect of PEG:CTI ratio on protein resistance and anticoagulant properties. J Biomed Mater Res A. 2012;100(4):856-862.
42. Alibeik S, Zhu S, Yau JW, Weitz JI, Brash JL. Modification of polyurethane with polyethylene glycol-corn trypsin inhibitor for inhibition of factor XIIa in blood contact. J Biomater Sci Polym Ed. 2011;23(15):1981-1993.